ClinicalTrials.gg
Not yet recruitingNCT07405918Updated Jul 7, 2026

3D Printed Customized Bone Graft for Alveolar Regeneration: Longitudinal Cohort Evaluation

An observational study in Periodontal Diseases and Periodontal Bone Loss, sponsored by University of Guarulhos. Not yet recruiting. Open to participants aged 15 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-07-07.

Primary conditionAlveolar Bone LossRegistry: Periodontal DiseasesReclassifiedWhy we changed it
Registry
Periodontal Diseases — the first condition term the registry derived for this study.
ClinicalTrials.gg
Alveolar Bone Loss
Why
  1. The study's listed conditions name Alveolar Bone Loss, a narrower term within Periodontal Diseases.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by University of Guarulhos · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
100
Ages
15 Years and older
Sex
All
01

Study summary

This study will evaluate the behavior of the implant-supported restorations (prosthesis) placed into the areas grafted with the 3D printed customized bone (personalized graft produced to fit a specific bone defect), as well as the volume contraction of the printed bone.

02

Conditions studied

  • Periodontal Diseases
  • Periodontal Bone Loss

Browse trials for

Keywords

  • Personalized bone graft
  • 3D printed customized bone block
  • Guided Bone Regeneration
  • Personalized Medicine
03

In context

Alveolar Bone Loss Reclassified

320 studies on the registry are indexed under Alveolar Bone Loss; 79 are open to participants now.

This study's planned enrollment of 100 is above the median of 51 across 46 observational studies indexed under Alveolar Bone Loss.

Browse Alveolar Bone Loss studies →

Lead sponsor

University of Guarulhos is the lead sponsor of 17 studies on the registry; 4 are open to participants now.

Compared within Alveolar Bone Loss, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Periodontal Diseases. The counts are of registry records indexed under each term, refreshed daily. How we classify →

04

Who can participate

Ages eligible
15 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Probability sample

Study population

This prospective cohort study will evaluate the peri-implant conditions of patients who received regenerative procedures using 3D-printed blocks at the UnG Clinic. To this end, participants will be selected from the UnG graduate clinic who received the regenerative treatment using 3D-printed blocks between 2019 and 2025. Participants selected for the study must sign the Informed Consent Form (ICF) after a verbal and written explanation of the project. Subjects will receive oral hygiene instruction and professional prophylaxis prior to clinical examinations.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Systemically healthy individuals
  • over 18 years of age
  • Subjects that received regenerative surgical treatment by customized 3D printed blocks.
  • Subjects must agree to participate in the study and agree to sign the .

Exclusion criteria

Exclusion Criteria:

  • Subjects with ilness that avoid their presence to the clinical evaluation
  • ISubjects who have lost the customized blocks
  • Subjects who do not agree to participate in the study will be excluded.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
100 participants (estimated)
Target follow-up
6 Years
Patient registry
Yes

Interventions

  • OtherClinical evaluation

    Clinical parmeters and radiographical analysis

06

What researchers measure

Primary outcomes

  1. Periodontal Clinical Parameter of the implants Placed in the Grafted area

    Marginal Bone Loss \< 2mm

    Time frame: 5 years

Secondary outcomes

  1. Bone Graft Volume Alteration

    Tomographic Volumetric Measurement (mm3) of the 3D printed graft after a period ranged between 1 to 6 years

    Time frame: 6 years

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Jul 2026; primary completion for Dec 2026, 5 months later.

Of 22 observational studies under Alveolar Bone Loss, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 27. This study's planned 5 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 21, 2026
First posted
Feb 12, 2026
StartEst.
Jul 1, 2026
Primary completionEst.
Dec 1, 2026
CompletionEst.
Dec 1, 2026
Last update
Jul 7, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 7, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07405918
Lead sponsor
University of Guarulhos
Responsible party
Jamil awad shibli (Principal Investigator, University of Guarulhos) — Principal investigator
First posted
Feb 12, 2026
Start date
Jul 1, 2026 (estimated)
Primary completion
Dec 1, 2026 (estimated)
Completion
Dec 1, 2026 (estimated)
Last update
Jul 7, 2026

Study contacts

Jamil A Shibli, DDS, PhD
Contact
jshibli@ung.br
+55 11 982593439

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion